新型毛细血管指尖采血装置在临床生化、全血细胞计数和糖化血红蛋白检测中的分析验证
本研究评估了Capillary Cup®指尖采血装置与静脉采血在临床生化、全血细胞计数和糖化血红蛋白检测中的分析等效性。63名健康参与者用于生化和糖化血红蛋白检测,67名用于全血细胞计数。结果显示所有参数与静脉采血高度相关(r=0.740-0.999,P<0.0001),均满足2025 CLIA可接受限,多数满足TEA阈值,表明该装置可作为静脉采血的潜在替代方案。
要点
- Capillary Cup®与静脉采血在生化、血常规和糖化血红蛋白检测中结果高度相关。
- 所有检测值均满足2025 CLIA可接受限,多数满足总允许误差阈值。
- 肌酐、甘油三酯、C反应蛋白和血小板计数有轻微偏差但仍可接受。
核心结论
- Capillary Cup®指尖采血装置在所有测试参数上提供与静脉采血分析等效的结果。
研究设计与样本
- 研究纳入63名健康参与者进行临床生化和糖化血红蛋白检测,67名进行全血细胞计数检测。
- 采用2025年CLIA可接受限和总允许误差阈值分析两种采血方法的结果差异。
主要发现
- Capillary Cup®样本与静脉样本在蛋白质、转氨酶、肾功能标志物、血脂、C反应蛋白、血细胞和血小板计数、白细胞分类、血红蛋白、血细胞比容和Wintrobe指数上呈强线性相关(r=0.740-0.999,P<0.0001)。
- 糖化血红蛋白可在单一试剂盒中与其他生化标志物同时准确测量(r=0.976,P<0.0001)。
- 所有值均满足2025 CLIA可接受限,大多数也满足TEA阈值。
- 肌酐、甘油三酯、C反应蛋白和血小板计数观察到轻微偏差,血小板计数可能受激活和聚集影响,但均在可接受限内并保持线性。
关键数值与推荐
- 2025 CLIA可接受限和总允许误差阈值用于评估分析等效性。
- 相关系数r=0.740-0.999,P<0.0001,糖化血红蛋白r=0.976,P<0.0001。
临床怎么用
- Capillary Cup®易于使用、减少浪费,可作为居家健康监测的潜在替代方案。
- 该装置可解决静脉通路困难的问题,并降低临床实践中医源性失血风险。
局限性
- 研究仅纳入健康参与者,未涉及患者群体。
- 血小板计数可能受激活和聚集影响,需注意轻微偏差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Capillary Cup® is a novel finger-stick blood collection device equipped with separation float technology to effectively isolate plasma and blood cell layers. This study aimed to evaluate its analytical equivalence compared to venipuncture sampling in clinical chemistry, complete blood count, and hemoglobin A1c testing. METHODS: Blood samples were collected from 63 healthy participants for clinical chemistry and hemoglobin A1c tests and 67 for complete blood count tests. Discrepancies between the Capillary Cup® and venipuncture sampling results were analyzed using the 2025 Clinical Laboratory Improvement Amendments (CLIA) acceptance limits and total allowable error (TEA) thresholds. RESULTS: The Capillary Cup® samples showed strong linear correlations with venipuncture samples across proteins, transaminases, kidney function markers, lipids, C-reactive protein, blood cell and platelet counts, white blood cell differentials, hemoglobin, hematocrit, and Wintrobe's indices (r = 0.740-0.999, P < 0.0001). Hemoglobin A1c was accurately measured alongside other clinical chemistry markers in a single kit (r = 0.976, P < 0.0001). All values met the 2025 CLIA acceptance limits, and most also met the TEA thresholds. Minor deviations were observed for creatinine, triglycerides, and C-reactive protein, as well as for platelet counts-potentially affected by activation and aggregation-but all remained within acceptance limits and demonstrated preserved linearity. CONCLUSIONS: The Capillary Cup® provides analytically equivalent results to venipuncture for all tested parameters. It is easy to use, reduces waste, and is a potential alternative for at-home health monitoring, addressing challenges in venous access, and reducing iatrogenic blood loss risk in clinical practice.
引用
- Sakai Y, Kato T, Saito M, et al. Analytical validation of a novel capillary finger-stick blood sampling device for clinical chemistry, complete blood count, and hemoglobin A1c testing. Clin Chim Acta. 2025. PMID: 41101441. doi:10.1016/j.cca.2025.120664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。